Chicago Partners Investment Group LLC lifted its position in Eli Lilly and Company (NYSE:LLY) by 39.7% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,726 shares of the company’s stock after purchasing an additional 1,627 shares during the quarter. Chicago Partners Investment Group LLC’s holdings in Eli Lilly and were worth $1,072,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently modified their holdings of the stock. AFT Forsyth & Company Inc. grew its holdings in Eli Lilly and by 0.8% during the fourth quarter. AFT Forsyth & Company Inc. now owns 6,695 shares of the company’s stock worth $1,130,000 after buying an additional 50 shares in the last quarter. Horizon Investment Services LLC grew its stake in shares of Eli Lilly and by 2.7% in the 4th quarter. Horizon Investment Services LLC now owns 1,904 shares of the company’s stock worth $321,000 after acquiring an additional 50 shares in the last quarter. CRA Financial Services LLC raised its holdings in shares of Eli Lilly and by 1.2% in the fourth quarter. CRA Financial Services LLC now owns 4,316 shares of the company’s stock valued at $729,000 after purchasing an additional 51 shares during the last quarter. Meridian Wealth Management LLC lifted its position in shares of Eli Lilly and by 2.9% during the fourth quarter. Meridian Wealth Management LLC now owns 1,887 shares of the company’s stock valued at $318,000 after purchasing an additional 53 shares in the last quarter. Finally, Park Avenue Securities LLC boosted its position in Eli Lilly and by 1.1% in the fourth quarter. Park Avenue Securities LLC now owns 5,091 shares of the company’s stock worth $860,000 after purchasing an additional 55 shares during the last quarter. 75.59% of the stock is owned by hedge funds and other institutional investors.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 125,284 shares of the business’s stock in a transaction dated Monday, March 8th. The shares were sold at an average price of $209.69, for a total value of $26,270,801.96. Following the transaction, the insider now owns 110,422,933 shares in the company, valued at $23,154,584,820.77. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jackson P. Tai bought 1,366 shares of the business’s stock in a transaction that occurred on Friday, April 30th. The stock was acquired at an average cost of $182.84 per share, for a total transaction of $249,759.44. Following the completion of the purchase, the director now directly owns 60,649 shares of the company’s stock, valued at $11,089,063.16. The disclosure for this purchase can be found here. Insiders own 0.09% of the company’s stock.
Eli Lilly and (NYSE:LLY) last released its earnings results on Monday, April 26th. The company reported $1.87 EPS for the quarter, missing the Zacks’ consensus estimate of $2.12 by ($0.25). Eli Lilly and had a net margin of 24.01% and a return on equity of 166.45%. The firm had revenue of $6.81 billion during the quarter, compared to the consensus estimate of $7.10 billion. During the same period in the prior year, the company earned $1.75 EPS. The firm’s revenue was up 16.1% compared to the same quarter last year. On average, analysts predict that Eli Lilly and Company will post 7.56 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 10th. Investors of record on Friday, May 14th will be issued a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 1.83%. Eli Lilly and’s dividend payout ratio is 56.29%.
A number of research firms have recently commented on LLY. Morgan Stanley lowered their target price on Eli Lilly and from $217.00 to $207.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 28th. Cowen boosted their target price on shares of Eli Lilly and from $195.00 to $235.00 and gave the company an “outperform” rating in a report on Friday, February 12th. Bank of America raised their price target on Eli Lilly and from $195.00 to $225.00 and gave the stock a “buy” rating in a report on Friday, January 22nd. Truist boosted their price objective on Eli Lilly and from $200.00 to $215.00 in a research note on Monday, February 1st. Finally, Truist Securities raised their target price on Eli Lilly and from $215.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, March 22nd. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $200.75.
About Eli Lilly and
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.